Ullem Scott B. 4

What Happened

• Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences (EW), exercised 13,000 option-derived shares on April 9, 2026 at an exercise price of $59.26 per share (total cost $770,337), acquiring 13,000 shares. On the same day he sold those 13,000 shares in two block transactions: 4,676 shares at a weighted average price of $80.50 ($376,401) and 8,324 shares at a weighted average price of $79.79 ($664,144), for total sale proceeds of $1,040,545. The filing also shows a derivative disposition entry of 13,000 shares at $0.00 reflecting the conversion/exercise of the derivative instrument.

Key Details

• Transaction date: April 9, 2026.
• Exercise: 13,000 shares at $59.26 each = $770,337 (acquired).
• Sales: 4,676 shares at $80.225–$80.75 (weighted avg $80.50) = $376,401; 8,324 shares at $79.21–$80.20 (weighted avg $79.79) = $664,144. Total sold = 13,000 shares for $1,040,545.
• Footnotes: Transactions were executed under a Rule 10b5-1 trading plan adopted July 29, 2025 (F1). F2/F3 note the sales were executed in multiple trades and the filing reports weighted-average prices; full trade-level details can be provided upon request.
• Shares owned after transaction: Not disclosed in this Form 4 filing.
• Filing timeliness: Form 4 filed with transaction date 2026-04-09 (same day), no late filing indicated.

Context

• This sequence (exercise of options followed by sale of an equal number of shares) is consistent with a cashless exercise or planned disposition: options were converted to shares and the resulting shares were sold the same day. Because the trades were executed under a pre-established 10b5-1 plan, they were pre-scheduled and not necessarily a contemporaneous judgment about company prospects.